Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success

The big-selling psoriasis drug has achieved healthy clinical remission rates in a Phase II trial for ulcerative colitis, and Celgene believes Otezla and another potential blockbuster, ozanimod, will help it build a significant presence in inflammatory bowel disease.